伊布替尼-话题@MedSci

vue-cli-subapp

#伊布替尼#

88篇内容 | 4845人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288708, encodeId=21921288e085f, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, objectType=article, longId=113567, objectId=c69011356e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69011356e79, replyNumber=0, likeNumber=46, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69011356e79, moduleTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69011356e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288707, encodeId=6cdf1288e0753, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=111399, objectId=185911139962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185911139962, replyNumber=0, likeNumber=48, createdTime=2017-09-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185911139962, moduleTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185911139962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288706, encodeId=0b4c1288e0664, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：伊布替尼开启边缘区淋巴瘤无化疗时代, objectType=article, longId=96889, objectId=64fb968890c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64fb968890c, replyNumber=0, likeNumber=99, createdTime=2017-04-26, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64fb968890c, moduleTitle=Blood：伊布替尼开启边缘区淋巴瘤无化疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64fb968890c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288705, encodeId=09541288e05d8, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, objectType=article, longId=94964, objectId=7a03949644f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a03949644f, replyNumber=0, likeNumber=92, createdTime=2017-04-08, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a03949644f, moduleTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a03949644f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288704, encodeId=bd121288e0430, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：如何治疗伊布替尼耐药的CLL患者？, objectType=article, longId=93305, objectId=e97a93305ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e97a93305ec, replyNumber=0, likeNumber=70, createdTime=2017-03-26, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e97a93305ec, moduleTitle=Blood：如何治疗伊布替尼耐药的CLL患者？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e97a93305ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

hongbochen

#伊布替尼#

伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）

2017-09-23

hongbochen

#伊布替尼#

重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-09-01

hongbochen

#伊布替尼#

Blood：伊布替尼开启边缘区淋巴瘤无化疗时代

2017-04-26

hongbochen

#伊布替尼#

一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效

2017-04-08

hongbochen

#伊布替尼#

Blood：如何治疗伊布替尼耐药的CLL患者？

2017-03-26